Recombinant alpha-fetoprotein (rEVO Biologics/Merrimack)

N/A

Report date: 2022/11/25 18:07:05

Base Information

Drug NameRecombinant alpha-fetoprotein (rEVO Biologics/Merrimack)
Drug Alias NameAFP - GTC/MerrimackrhAFP - GTC/MerrimackRecombinant human alpha fetoproteinMM-093ABI-001
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionImmunosuppressants
TargetsAlpha-fetoprotein
Therapy Area/IndicationsPsoriasisUveitisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerrimack Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerrimack Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPsoriasisUveitisArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A